Rupee ends nearly flat; weak equities erode India-Pakistan truce-spurred rise
MUMBAI, May 13 (Reuters) - The Indian rupee closed nearly flat on Tuesday as a fall in local equities and dollar bids from state-run banks ate into the currency's early gains spurred by the cessation of military hostilities between India and Pakistan.
The rupee touched a peak of 84.6350 in early trading before ending at 85.33 against the U.S. dollar, nearly unchanged from its close at 85.37 on Friday.
The benchmark equity indexes, the BSE Sensex (.BSESN), opens new tab and Nifty 50 (.NSEI), opens new tab, fell about 1.5% each on fears of foreign flows moving to China after its trade pact with U.S. and on profit booking after the previous day's near 4% rally. India's bond and currency markets were closed on Monday.
On Monday, U.S. and China announced an agreement to reduce reciprocal tariff reductions for the next three months.
"A rally in China stocks might see modest near-term underperformance of India stocks," Nomura said in a note, raising its allocation to Chinese equities to a "tactical overweight."
The firm said that it maintains an overweight position on Indian equities but will fund its allocation to China by trimming exposure to India.
On the day, two traders also pointed to strong bids from state-run banks weighing on the rupee. A large state-run bank was persistently bidding for dollar, a trader at a mid-sized foreign bank said.
The offshore Chinese yuan was nearly flat after touching a six-month peak earlier in the session. The dollar index was slightly lower at 101.6 while U.S. bond yields dipped.
Investors await consumer price inflation data from India and the U.S. due later in the day.
While India's April CPI is expected to have eased to a near six-year low of 3.27%, month-on-month core U.S. CPI likely rose to 0.3%, according to economists polled by Reuters.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
Otsuka's kidney disease therapy trial results heat up battle with rival Vera
June 6 (Reuters) - Otsuka's (4578.T), opens new tab experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new treatment with rival Vera Therapeutics (VERA.O), opens new tab. The Japan-based company said on Friday its therapy, sibeprenlimab, cut proteinuria levels by 51.2% in patients with Immunoglobulin A Nephropathy, also known as Berger's disease, at nine months in a late-stage trial. The data comes just days after Vera said its drug, atacicept, reduced protein levels in patients' urine by 46%, compared with a 7% reduction with a placebo, meeting the main goal of a 428-patient late-stage study. Shares of the U.S.-based drug developer slid 31% to $20.89. Analysts, however, said that though data from Otsuka's sibeprenlimab might look superior, it was unlikely that doctors would interpret it that way. The difference between the two datasets is not too clinically diverse to affect demand for Vera's drug, said Jefferies analyst Farzin Haque. Berger's disease causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure. Analysts have estimated the U.S. market for its treatments could be worth as much as $10 billion. Otsuka has already applied for the FDA's accelerated approval for its therapy to treat the disease. However, its sales would largely depend on whether the treatment can improve kidney function, analysts said. Even if the drug gains accelerated approval, Otsuka said it plans to study whether it can preserve the organ's ability to filter toxins from blood, measured as the glomerular filtration rate (eGFR). "The magnitude of the protein reduction should translate into eGFR preservation down the line, because ultimately that's what patients are going to be asking for," Dana Rizk, the trial's investigator and a professor of medicine at the University of Alabama in Birmingham, told Reuters. The study is expected to be completed in early 2026.
Telegraph
12 hours ago
- Telegraph
British AI start-up embroiled in sex assault claims after going bust
The acrimonious collapse of one of Britain's most feted AI start-ups came after it faced allegations that a senior executive sexually assaulted a former member of staff, The Telegraph can reveal. The alleged assault took place at a hotel in India in 2022 and was reported to the police at the time. A board member alerted management to the claims, which were also the subject of a public petition to remove the executive. The Telegraph is aware of the identities of the alleged perpetrator and victim but cannot name them for legal reasons. The alleged assault was said to have taken place when the executive was on holiday and not on company business. The individual has since left the company. However, The Telegraph understands the incident remains the subject of ongoing legal proceedings in India against the police for alleged failure to investigate the complaint properly. A police filing reported in Indian media at the time, which did not name Builder AI, alleged the victim was forced to take a pill at 3am after meeting the executive in a hotel bar, and was later seriously assaulted in a hotel room. The alleged victim told her sister and friends, who urged her to take the incident to the police. It is understood the executive denied any wrongdoing. Builder AI commissioned an internal investigation into the matter, led by the company's general counsel. Sachin Dev Duggal, Builder AI's ousted chief and founder, is said to have recused himself from the investigation and received the final report. There is no suggestion of wrongdoing by Mr Duggal. Despite the investigation, Manpreet Ratia, Builder AI's new chief executive, this weekend insisted the full board and wider executive team at Builder AI had not been informed of the matter. Builder AI said: 'The matter was first raised with the company by an individual board member, acting in their personal capacity. 'Based on internal emails reviewed to date, it appears that Sachin Duggal recused himself from involvement in the matter. 'The company has been informed that a report was submitted by the general counsel to Sachin Duggal and the individual board member, concluding that no further action was warranted. This report was not shared with the broader board or the executive leadership. 'For avoidance of doubt, the full board of directors and the executive team were not made aware of this matter at the time it arose.' The statement added the wider board was first made aware of the claims after being contacted by The Telegraph, and that the investigation had not been overseen or directed by the board. The sexual assault claims at Builder AI, which have not previously been reported, come days after the business filed for bankruptcy in the US amid reports that inflated sales precipitated its dramatic collapse. Builder AI's lenders pulled support from the business earlier in May after forecast sales failed to materialise and came in far below expectations. Predicted sales of $220m (£163m) came in at closer to $50m. The company has been served with subpoenas by US prosecutors in New York, who have asked for information on its financial reporting and accounting, The Telegraph understands. Mr Duggal, Builder AI's founder and 'chief wizard', launched the business in 2016 with the aim of making building an app as 'easy as ordering a pizza'. The company offered what it called 'human-assisted AI', using a chatbot called Natasha and human contractors to quickly and cheaply build apps. The company raised $250m from investors, including Microsoft and venture capital investors Jungle Ventures and Insight Partners, who bought into Mr Duggal's vision. However, Mr Duggal was ousted in February after the board found that the company's revenues for 2024 were far lower than had been forecast. The events ultimately led lenders to pull $40m from the company's accounts in May, according to a letter to investors, forcing the UK-headquartered start-up to file for bankruptcy in the US. Last week, the Financial Times reported Builder AI was suspected by former employees to have engaged in multiple methods to boost revenues, including alleged circular transactions and deals with resellers that took years to pay up. A source familiar with the company's finances, however, denied this, and insisted its revenues were always reported properly, transparent and said that business with partners was legitimate. Builder AI collapsed with liabilities of up to $100m, bankruptcy filings show. According to the note to investors, the company owed more than $88m to cloud providers, such as Amazon. The start-up had been widely hailed as UK AI champion. Mr Duggal was named an EY World Entrepreneur of the Year in 2024. Its failure, and the sexual assault allegations, threaten to cast a shadow over Britain's AI ambitions.
Powys County Times
15 hours ago
- Powys County Times
Letter: Britain must not be dragged back into the EU
There is a clear and compelling case for Britain to remain a self-governing, sovereign nation, under its own parliament, courts, and laws, pursuing global trade on its own terms. What Keir Starmer has agreed with Brussels stands in stark opposition to that principle. His new deal quietly re-submits the UK to the EU's law-making machinery through so-called 'dynamic alignment,' stripping away regulatory autonomy without voting rights or formal influence. This is not co-operation, it's rule-taking. Worse still, this violates the terms of our recently signed Asia-Pacific trade pact (CPTPP) and risks legal action that will damage Britain's global credibility. What message does this send to future trade partners? That Britain cannot be trusted to stick to its own treaties? That any agreement is temporary until Labour reopens the backdoor to Brussels? Starmer's move was done without a public mandate, with no clear economic benefit, and likely at great cost to key growth sectors like biosciences and agri-tech, now vulnerable to intrusive EU regulation. The EU did not demand such concessions from New Zealand or other sovereign nations. Why should we be the exception? British farmers have already warned that any SPS (sanitary and phytosanitary) deal must protect our right to make our own production rules. Yet Starmer's approach risks sacrificing that independence under the false promise of smoother trade. From live animal exports to cosmetic testing, will the UK now be forced to unwind hard-won ethical reforms to satisfy Brussels? Britain didn't vote for a satellite status. We must not be dragged back step by step into the EU's orbit through political sleight of hand.
